ProKidney Corp. (NASDAQ:PROK) Insider Control Empresarial De Capital Purchases 268,105 Shares of Stock

ProKidney Corp. (NASDAQ:PROK) insider Control Empresarial De Capital purchased 268,105 shares of the firm’s stock in a transaction that occurred on Monday, April 14th. The stock was bought at an average price of $0.73 per share, with a total value of $195,716.65. Following the transaction, the insider now directly owns 72,862,330 shares in the company, valued at $53,189,500.90. This trade represents a 0.37 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Control Empresarial De Capital also recently made the following trade(s):

• On Thursday, April 10th, Control Empresarial De Capital purchased 1,032,218 shares of ProKidney stock. The shares were bought at an average price of $0.61 per share, with a total value of $629,652.98.

ProKidney Stock Performance

Shares of PROK opened at $0.80 on Thursday. ProKidney Corp. has a twelve month low of $0.46 and a twelve month high of $4.44. The firm’s 50 day moving average price is $1.07 and its 200 day moving average price is $1.52. The firm has a market cap of $234.16 million, a PE ratio of -1.45 and a beta of 1.52.

ProKidney (NASDAQ:PROK) last announced its earnings results on Monday, March 17th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The company had revenue of $0.08 million during the quarter. On average, sell-side analysts anticipate that ProKidney Corp. will post -0.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ProKidney

Institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its holdings in shares of ProKidney by 150.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 749,718 shares of the company’s stock worth $1,439,000 after acquiring an additional 450,548 shares during the period. The Manufacturers Life Insurance Company raised its holdings in ProKidney by 54.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 37,981 shares of the company’s stock worth $73,000 after buying an additional 13,415 shares during the period. State Street Corp lifted its position in ProKidney by 16.2% in the 3rd quarter. State Street Corp now owns 1,428,318 shares of the company’s stock valued at $2,742,000 after acquiring an additional 198,836 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of ProKidney in the third quarter valued at about $41,000. Finally, Barclays PLC grew its holdings in shares of ProKidney by 575.7% during the third quarter. Barclays PLC now owns 146,321 shares of the company’s stock worth $281,000 after buying an additional 124,667 shares in the last quarter. Institutional investors and hedge funds own 51.59% of the company’s stock.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.